Literature DB >> 25070108

Interaction of Interferon gamma-induced reactive oxygen species with ceftazidime leads to synergistic killing of intracellular Burkholderia pseudomallei.

Kara Mosovsky1, Ediane Silva1, Ryan Troyer1, Katie Propst-Graham1, Steven Dow2.   

Abstract

Burkholderia pseudomallei, a facultative intracellular pathogen, causes severe infections and is inherently refractory to many antibiotics. Previous studies from our group have shown that interferon gamma (IFN-γ) interacts synergistically with the antibiotic ceftazidime to kill bacteria in infected macrophages. The present study aimed to identify the underlying mechanism of that interaction. We first showed that blocking reactive oxygen species (ROS) pathways reversed IFN-γ- and ceftazidime-mediated killing, which led to our hypothesis that IFN-γ-induced ROS interacted with ceftazidime to synergistically kill Burkholderia bacteria. Consistent with this hypothesis, we also observed that buthionine sulfoximine (BSO), another inducer of ROS, could substitute for IFN-γ to similarly potentiate the effect of ceftazidime on intracellular killing. Next, we observed that IFN-γ induced ROS-mediated killing of intracellular but not extracellular bacteria. On the other hand, ceftazidime effectively reduced extracellular bacteria but was not capable of intracellular killing when applied at 10 μg/ml. We investigated the exact role of IFN-γ-induced ROS responses on intracellular bacteria and notably observed a lack of actin polymerization associated with Burkholderia bacteria in IFN-γ-treated macrophages, which led to our finding that IFN-γ-induced ROS blocks vacuolar escape. Based on these results, we propose a model in which synergistically reduced bacterial burden is achieved primarily through separate and compartmentalized killing: intracellular killing by IFN-γ-induced ROS responses and extracellular killing by ceftazidime. Our findings suggest a means of enhancing antibiotic activity against Burkholderia bacteria through combination with drugs that induce ROS pathways or otherwise target intracellular spread and/or replication of bacteria.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25070108      PMCID: PMC4187985          DOI: 10.1128/AAC.02781-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  55 in total

1.  Burkholderia pseudomallei induces cell fusion and actin-associated membrane protrusion: a possible mechanism for cell-to-cell spreading.

Authors:  W Kespichayawattana; S Rattanachetkul; T Wanun; P Utaisincharoen; S Sirisinha
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

2.  Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.

Authors:  Girija Dhamdhere; Ganesh Krishnamoorthy; Helen I Zgurskaya
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

3.  Burkholderia pseudomallei type III secretion system mutants exhibit delayed vacuolar escape phenotypes in RAW 264.7 murine macrophages.

Authors:  Mary N Burtnick; Paul J Brett; Vinod Nair; Jonathan M Warawa; Donald E Woods; Frank C Gherardini
Journal:  Infect Immun       Date:  2008-04-28       Impact factor: 3.441

4.  Burkholderia mallei cluster 1 type VI secretion mutants exhibit growth and actin polymerization defects in RAW 264.7 murine macrophages.

Authors:  Mary N Burtnick; David DeShazer; Vinod Nair; Frank C Gherardini; Paul J Brett
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

5.  Depletion of glutathione by inhibition of biosynthesis.

Authors:  O W Griffith
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

Review 6.  Management of melioidosis.

Authors:  Vanaporn Wuthiekanun; Sharon J Peacock
Journal:  Expert Rev Anti Infect Ther       Date:  2006-06       Impact factor: 5.091

7.  Role of inducible nitric oxide synthase and NADPH oxidase in early control of Burkholderia pseudomallei infection in mice.

Authors:  Katrin Breitbach; Sonja Klocke; Thomas Tschernig; Nico van Rooijen; Ulrich Baumann; Ivo Steinmetz
Journal:  Infect Immun       Date:  2006-09-25       Impact factor: 3.441

8.  Burkholderia pseudomallei interferes with inducible nitric oxide synthase (iNOS) production: a possible mechanism of evading macrophage killing.

Authors:  P Utaisincharoen; N Tangthawornchaikul; W Kespichayawattana; P Chaisuriya; S Sirisinha
Journal:  Microbiol Immunol       Date:  2001       Impact factor: 1.955

9.  Intracellular survival of Burkholderia pseudomallei.

Authors:  A L Jones; T J Beveridge; D E Woods
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

Review 10.  Regulation of glutathione synthesis.

Authors:  Shelly C Lu
Journal:  Mol Aspects Med       Date:  2008-06-14
View more
  4 in total

1.  Cell free mitochondrial DNA in serum and milk associated with bovine mastitis: a pilot study.

Authors:  Geeta Devi Leishangthem; Niraj Kumar Singh; Nittin Dev Singh; Gursimran Filia; Amarjit Singh
Journal:  Vet Res Commun       Date:  2018-08-25       Impact factor: 2.459

2.  Adoptive transfer of placental ischemia-stimulated natural killer cells causes a preeclampsia-like phenotype in pregnant rats.

Authors:  Olivia K Travis; Cedar Baik; Geilda A Tardo; Lorena Amaral; Carmilya Jackson; Mallory Greer; Chelsea Giachelli; Tarek Ibrahim; Owen T Herrock; Jan M Williams; Denise C Cornelius
Journal:  Am J Reprod Immunol       Date:  2020-12-27       Impact factor: 3.777

3.  Burkholderia pseudomallei infection presenting with a lung abscess and osteomyelitis in an adult man: A case report.

Authors:  Lei Huang; Zhi Yang; Xiao-Ping Zhou; Jun-Rong Wu
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

4.  IL-18 binding protein (IL-18BP) as a novel radiation countermeasure after radiation exposure in mice.

Authors:  Xianghong Li; Wanchang Cui; Lisa Hull; Li Wang; Tianzheng Yu; Mang Xiao
Journal:  Sci Rep       Date:  2020-10-29       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.